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4-Phenylquinolin-2(1H)-one (4-PQ) derivatives can induce cancer cell apoptosis. Additional new 4-PQ analogs were
investigated as more effective, less toxic antitumour agents.
EXPERIMENTAL APPROACH
Forty-five 6,7,8-substituted 4-substituted benzyloxyquinolin-2(1H)-one derivatives were synthesized. Antiproliferative activities
were evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliun bromide assay and structure–activity relationship
correlations were established. Compounds 9b, 9c, 9e and 11e were also evaluated against the National Cancer Institute-60
human cancer cell line panel. Hoechst 33258 and Annexin V-FITC/PI staining assays were used to detect apoptosis, while
inhibition of microtubule polymerization was assayed by fluorescence microscopy. Effects on the cell cycle were assessed by
flow cytometry and on apoptosis-related proteins (active caspase-3, -8 and -9, procaspase-3, -8, -9, PARP, Bid, Bcl-xL and
Bcl-2) by Western blotting.
KEY RESULTS
Nine 6,7,8-substituted 4-substituted benzyloxyquinolin-2(1H)-one derivatives (7e, 8e, 9b, 9c, 9e, 10c, 10e, 11c and 11e)
displayed high potency against HL-60, Hep3B, H460, and COLO 205 cancer cells (IC50 < 1 μM) without affecting Detroit 551
normal human cells (IC50 > 50 μM). Particularly, compound 11e exhibited nanomolar potency against COLO 205 cancer cells.
Mechanistic studies indicated that compound 11e disrupted microtubule assembly and induced G2/M arrest, polyploidy and
apoptosis via the intrinsic and extrinsic signalling pathways. Activation of JNK could play a role in TRAIL-induced COLO 205
apoptosis.
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CONCLUSION AND IMPLICATIONS
New quinolone derivatives were identified as potential pro-apoptotic agents. Compound 11e could be a promising lead
compound for future antitumour agent development.
Abbreviations
4-PQ, 4-phenylquinolin-2(1H)-one; AGT, alkylguanine-DNA alkyltransferase; BG, benzylguanine; CDK, cyclin dependent
kinase; NCI, National Cancer Institute; PPA, polyphosphoric acid; SAR, structure–activity relationship
Introduction
Cancer is presently a worldwide health problem and the
leading cause of death in the United States and other devel-
oped countries (Rastogi et al., 2004). Cancer is a formidable
disease caused by disordered cell growth and invasion of
tissues and organs. While various therapies and strategies have
been developed to treat cancer, most of them have limitations.
Thus, new anticancer drugs are continually needed. The main
challenge facing clinical cancer therapy is to find a specific
approach that kills malignant cells with no or few adverse
effects on normal tissues and considerable attempts have been
made to develop innovative, safe and effective methods to
defeat cancer. While scientists have discovered many agents
with cytostatic action against cancer cells (Liu et al., 2007;
Folger et al., 2011), increasing understanding of the biological
processes involved in cancer cell survival has led to the design
and discovery of better targeted, novel therapeutic anticancer
drugs. For several chemotherapeutic agents, a direct correla-
tion has been found between antitumour efficacy and ability
to induce apoptosis (Kaufmann and Earnshaw, 2000). Thus,
approaches aimed at promoting apoptosis in cancer cells have
gained importance in cancer research (Fesik, 2005; Fischer and
Schulze-Osthoff, 2005).
Heterobicycles are indispensable structural units in com-
pounds with a broad range of biological activities. Among
various nitrogen-containing fused heterocyclic skeletons, qui-
noline and quinolone structures are important components
prevalent in a vast array of biological systems. Compounds
with a quinoline nucleus exhibit various pharmacological
properties, including antioxidant (Chung and Woo, 2001;
Zhang et al., 2013), anti-inflammatory (Baba et al., 1996;
Mukherjee and Pal, 2013), antibacterial (Cheng et al., 2013),
anti-human immunodeficiency virus (Freeman et al., 2004;
Hopkins et al., 2004), antimalarial (Cornut et al., 2013; Pandey
et al., 2013), antituberculosis (Lilienkampf et al., 2009), anti-
Alzheimer’s disease (Fiorito et al., 2013), anticancer (Wang
et al., 2011; Abonia et al., 2012; Chan et al., 2012) activities.
Accordingly, Solomon and Lee described quinoline-
containing subunits as ‘privileged structures’ for drug devel-
opment (Solomon and Lee, 2011). 2-Quinolone [quinolin-
2(1H)-one], also called 1-aza coumarin or carbostyril, and
4-quinolone are structural isomers. The 2-quinolone skeleton
is a fertile source of biologically active compounds, including
a wide spectrum of alkaloids investigated for antitumour activ-
ity (Ito et al., 2004; He et al., 2005; Nakashima et al., 2012). In
our previous investigation, 6,7-methylenedioxy-4-substituted
phenylquinolin-2(1H)-one derivatives (4-phenylquinolin-
2(1H)-ones; 4-PQs) were identified as novel apoptosis-
inducing agents (Figure 1) (Chen et al., 2013b). Recently, Arya
and Agarwal reported that 4-hydroxyquinolin-2(1H)-one
derivatives, prepared efficiently through microwave irradia-
tion, showed strong photo-antiproliferative activity (Arya and
Agarwal, 2007). Thus, we have directed our focus onto 4-PQ
analogues as inducers of apoptosis. In our current study, we
targeted the 2-quinolone structure as a basic scaffold of new
derivatives with different substituents.
Purine-based compounds such as olomoucine and rosco-
vitine (Figure 1), which contain other heterobicyclic ring
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These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://
www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are
permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (a,bAlexander et al., 2013a,b).
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of cyclin dependent kinase (CDK) and are useful cell prolif-
eration inhibitors in the treatment of cancer (Jorda et al.,
2011). Structure–activity relationship (SAR) studies on CDK
inhibitors demonstrated that a small hydrophobic group
such as a non-polar benzyl group at the O6- or N6-position
of the heterobicycle maximized CDK inhibition (Gibson
et al., 2002; Zatloukal et al., 2013). In addition, numerous
CDK inhibitor-related compounds that contain benzyl or
aryl methyl groups on different core scaffolds, such as
pyrazolo[1,5-a]pyrimidines (Paruch et al., 2007), quinazolin-
4-amines (Mott et al., 2009), pyrimidine (Coombs et al., 2013)
and aminopurine (Doležal et al., 2006) (Figure 1), have
been studied. Furthermore, a series of 6-(benzyloxy)-2-
(aryldiazenyl)-9H-purine derivatives were reported to act as
prodrugs of O6-benzylguanine (O6-BG; Figure 1), which selec-
tively targets O6-alkylguanine-DNA alkyltransferase (AGT) in
hypoxic tumour cells (Zhu et al., 2013). The AGT protein
plays a critical role in DNA repair, which can be exploited in
chemotherapeutic treatment of neoplastic cells (Dolan and
Pegg, 1997; Daniels et al., 2000). Alkylation of AGT with the
benzyl group of O6-BG results in complete depletion of the
alkyltransferase protein. Consequently, numerous O6-BG
analogs have been developed as AGT inhibitors (Chae et al.,
1995; Terashima and Kohda, 1998). Ruiz et al. (2008) reported
that a family of quinolinone compounds acted as novel non-
nucleosidic AGT inhibitors. These quinolinones could reach
the critical catalytic residue Cys145 buried deep within the
binding groove, occupy the catalytic cleft of human DNA
repair AGT protein and act as substrate mimics of the
O6-guanine moiety.
Furthermore, the activity of biologically proven antican-
cer pharmacophores can be enhanced by introducing appro-
priate substitutions on the chemical scaffolds. In medicinal
chemistry, shortening or lengthening chain length is a useful
tactic to improve the affinity of target binding. Some reports
have demonstrated that the pro-apoptotic (anti-tumour)
activity of certain compounds was dramatically improved by
slightly changing the length and spacing of lateral branches,
such as benzyl and other alkyl-aromatic side chains, on core
skeletons (Al-Obaid et al., 2009; Font et al., 2011). Such explo-
ration and utilization of chemical diversity relative to phar-
macological space is an ongoing drug discovery strategy,
referred to as privileged-substructure-based diversity-oriented
synthesis (Oh and Park, 2011). Based on this strategy, as well
as the structures shown in Figure 1, we proposed addition of
a substituted benzyl (C ring) side chain linked at the
O4-position of 4-hydroxyquinolin-2(1H)-one (2-quinolone
scaffold) as a possible strategy for discovering new leads with
pro-apoptotic bioactivity. The flexibility of the benzyl moiety
might provide better antitumour activity compared with our
earlier 4-PQ derivatives (Figure 1). Therefore, we designed a
series of 4-benzyloxyquinolin-2(1H)-one analogues 7a–e ∼
15a–e, with the general structures of target compounds
depicted in Figure 1. To the best of our knowledge, this
is the first evaluation of 2-quinolone analogues bearing
an O4-benzyl moiety against cancer. The goal of the
current study was to discover more effective and less toxic
antitumour agents and contribute to the SAR profile of
2-quinolones with anti-proliferative activity and pro-
apoptotic activities in cancer cells.
Figure 1
The structures of some anticancer agents and the general structure of the target compounds (7a–e ∼ 15a–e).
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Methods
Materials and physical measurements
All solvents and reagents were obtained commercially and
used without further purification. The progress of all reac-
tions was monitored by TLC on 2 × 6 cm pre-coated silica gel
60 F254 plates of thickness 0.25 mm (Merck KGaA, Darmstadt,
Germany). The chromatograms were visualized under UV at
254–366 nm. Column chromatography was performed using
silica gel 60 (Merck KGaA, particle size 0.063–0.200 mm).
Melting points (mp) were determined with a Yanaco
MP-500D melting point apparatus (Yanaco New Science Inc.,
Kyoto, Japan) and are uncorrected. IR spectra were recorded
on Shimadzu IR-Prestige-21 spectrophotometers (Shimadzu
Corp., Kyoto, Japan) as KBr pellets. The one-dimensional
NMR (1H and 13C) spectra were obtained on a Bruker Avance
DPX-200 FT-NMR spectrometer (Bruker Corp., Billerica, MA,
USA) at room temperature. The two-dimensional NMR
spectra were obtained on a Bruker Avance DPX-400 FT-NMR
spectrometer (Bruker Corp.) and chemical shifts were
expressed in parts per million (ppm, δ). The following abbre-
viations are used: s, singlet; d, doublet; t, triplet; dd, double
doublet and m, multiplet. Mass spectra were performed at the
Instrument Center of National Science Council at National
Chung Hsing University (Taichung City, Taiwan) using a
Finnigan ThermoQuest MAT 95 XL (EI-MS) (Thermo Fisher
Scientific Inc., Waltham, MA, USA).
General procedure for the synthesis of
4-hydroxyquinolin-2(1H)-one
derivatives (5a–i)
4-Hydroxyquinolin-2(1H)-one derivatives 5a–i were prepared
by ‘one-pot’ cyclization in polyphosphoric acid (PPA). A
mixture of the appropriate substituted aniline 1a–i (1 equiv)
and diethylmalonate (2) (1.2 equiv) was heated with PPA (five
to six times by weight) at 130°C for 2–6 h (TLC monitoring).
Then, the mixture was cooled and diluted with water. A gum
solidified upon standing overnight and the precipitate was
filtered, washed with water and air-dried to provide 5a–i with
sufficient purity for the next reaction. Physical and spectro-
scopic data for 5a are given in the succeeding text; the data
for the remaining compounds are provided as Supporting
Information.
4-Hydroxyquinolin-2(1H)-one (5a)
(Mohamed, 1991; Nadaraj et al., 2006; Arya
and Agarwal, 2007; Park et al., 2007; Zhang
et al., 2008)
Compound 5a (3.48 g, 21.59 mmol) was obtained from
aniline (1a) (3.82 g, 41.01 mmol) and diethylmalonate
(2) (7.88 g, 49.20 mmol); yield: 53%; light-yellow solid;
mp: 276–278°C; IR (KBr) ν (cm−1): 1660 (C = O); 1H NMR
(200 MHz, DMSO-d6) δ (ppm): 5.77 (s, 1H, H–3), 7.12
(t, J = 7.5 Hz, 1H, H–6), 7.26 (d, J = 8.2 Hz, 1H, H–8), 7.47
(t, J = 7.8 Hz, 1H, H–7), 7.77 (d, J = 8.0 Hz, 1H, H–5), 11.28
(br. s, 1H, NH); 13C NMR (50 MHz, DMSO-d6) δ (ppm): 98.56,
115.48, 115.63, 121.61, 123.11, 131.33, 139.55, 163.05,
164.18; MS (EI, 70 eV) m/z: 161.1[M]+; HRMS (EI) m/z: calcu-
lated for C9H7NO2: 161.0477; found: 161.0472.
General procedure for the synthesis of
6,7,8-substituted 4-substituted
benyloxyquinolin-2(1H)-one derivatives
(7a–e, 8a–e, 9a–e, 10a–e, 11a–e, 12a–e,
13a–e, 14a–e, 15a–e)
A mixture of 4-hydroxyquinolin-2(1H)-one derivatives 5a–i
(1 equiv) and K2CO3 (2 equiv) in DMF (10–20 mL) was heated
at 90°C for 1–2 h. The appropriate benzyl chloride or bromide
(6a–e, 1–1.4 equiv) was added and the mixture was heated at
80–90°C for 1–6 h. Reaction completion was confirmed by
TLC monitoring. The mixture was poured into ice water
(200 mL) and the precipitated solid was collected by filtration
and then washed with water. The residue was treated with
ethyl acetate (EtOAc) and purified by recrystallization. If no
solid was formed after the addition of ice water, then the
reaction mixture was extracted with EtOAc (3 × 100 mL). The
combined organic layers were dried over anhydrous MgSO4
before evaporation of solvent in vacuo. The residue was iso-
lated by column chromatography (silica gel, EtOAc as eluate)
and then recrystallized to give the corresponding pure prod-
ucts, 4-benzyloxyquinolin-2(1H)-one derivatives 7a–e, 8a–e,
9a–e, 10a–e, 11a–e, 12a–e, 13a–e, 14a–e and 15a–e. Physi-
cal and spectroscopic data for 11e are given as examples; the




Compound 11e (0.70 g, 2.05 mmol) was obtained from 5e
(1.12 g, 5.86 mmol) and 3,5-dimethoxybenzyl bromide
(1.48 g, 6.40 mmol); yield: 35%; white crystal; mp: 217–
219°C; IR (KBr) ν (cm−1): 1674 (C = O); 1H NMR (200 MHz,
DMSO-d6) δ (ppm): 3.74 (s, 6H, 3′, 5′–OCH3), 3.76 (s, 3H,
6–OCH3), 5.20 (s, 2H, –O–CH2–), 5.94 (s, 1H, H–3), 6.47 (dd,
J = 2.2,2.2 Hz, 1H, H–4′), 6.66 (d, J = 2.2 Hz, 2H, H–2′, H–6′),
7.14–7.26 (m, 3H, H–5,7,8), 11.32 (br. s, 1H, NH); 13C NMR
(50 MHz, DMSO-d6) δ (ppm): 55.63 (2C), 55.78, 70.05, 98.71,
100.04, 104.17, 105.62 (2C), 115.50, 117.18, 120.50, 133.55,
138.76, 154.43, 161.07 (2C), 161.89, 163.23; MS (EI, 70 eV)




assay for antiproliferative activity
Human tumour cell lines (HTCLs) of the cancer screening
panel were maintained in RPMI-1640 medium supplemented
with 10% FBS (GIBCO®, Life Technologies, Grand Island, NY,
USA), penicillin (100 U·mL−1)/streptomycin (100 μg·mL−1)
(GIBCO, Life Technologies) and 1% L-glutamine (GIBCO, Life
Technologies) at 37°C in a humidified atmosphere containing
5% CO2. Human hepatoma Hep 3B and normal skin Detroit
551 cells were maintained in DMEM medium supplemented
with 10% FBS (GIBCO, Life Technologies), penicillin
(100 U·mL−1)/streptomycin (100 μg·mL−1) (GIBCO, Life Tech-
nologies) and 1% L-glutamine (GIBCO, Life Technologies) at
37°C in a humidified atmosphere containing 5% CO2. Loga-
rithmically growing cancer cells were used for all experiments.
The HTCLs were treated with vehicle or test compounds for
48 h. Cell growth rate was determined by MTT reduction
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assay (Mosmann, 1983). After 48 h treatment, cell growth rate
was measured on an ELISA reader at a wavelength of 570 nm
and the IC50 values of test compounds were calculated.
In vitro National Cancer Institute (NCI)-60
HTCL panel
In vitro cytotoxic activities were evaluated through the Devel-
opmental Therapeutic Program (DTP) of the NCI (Shoemaker,
2006). For more information on the anticancer screening
protocol, please see: http://dtp.nci.nih.gov/branches/btb/
ivclsp.html.
Cell morphology and Hoechst 33258 staining
COLO 205 cells were plated at a density of 2.5 × 105 cells per
well in 12-well plates and then incubated with 50 nM of
compound 11e for 12 to 48 h. Cells were directly examined
and photographed under a contrast-phase microscope. Nuclei
were stained with Hoechst 33258 (bis-benzimide; Sigma-
Aldrich, St. Louis, MO, USA) to detect chromatin condensa-
tion or nuclear fragmentation, features of apoptosis. After 0,
12, 24, 36 and 48 h, 11e-treated cells were stained with
5 μg·mL−1 Hoechst 33258 for 10 min. After washing twice
with PBS, cells were fixed with 4% paraformaldehyde (PFA) in
PBS for 10 min at 25°C. Fluorescence of the soluble DNA
(apoptotic) fragments was measured in a Leica DMIL Inverted
Microscope (Leica Microsystems GmbH, Wetzlar, Germany)
at an excitation wavelength of 365 nm and emission wave-
length of 460 nm.
Apoptosis studies
Determination of apoptotic cells by fluorescent staining was
carried out as described previously (van Engeland et al., 1998;
Zhuang et al., 2013). The Annexin V-FITC Apoptosis Detec-
tion Kit was obtained from Strong Biotech Corporation
(Taipei, Taiwan). The COLO 205 cells (2 × 105 cells·per well)
were fluorescently labelled for detection of apoptotic and
necrotic cells by adding 100 μL of binding buffer, 2 μL of
Annexin V-FITC and 2 μL of propidium iodide (PI) to each
sample. Samples were mixed gently and incubated at room
temperature in the dark for 15 min. Binding buffer (300 μL)
was added to each sample immediately before flow cytomet-
ric analysis. A minimum of 10 000 cells within the gated
region was analysed.
Flow cytometric analysis for cell cycle
Compound 11e (final concentration 50 nM) was added to
COLO 205 cells for 0, 12, 24, 36 and 48 h. Cells were fixed in
70% EtOH overnight, washed twice and resuspended in PBS
containing 20 μg·mL−1 PI, 0.2 mg·mL−1 RNase A and 0.1%
Triton X-100 in the dark. After 30 min incubation at 37°C,
cell cycle distribution was analysed using ModFit LT Software
(Verity Software House, Topsham, ME, USA) in a BD FACS-
Canto flow cytometer (Becton Dickinson, San Jose, CA, USA).
Molecular modelling
The crystal structure of microtubules in complex with N-
deacetyl-N-(2-mercaptoacetyl)-colchicine (DAMA-colchicine)
was downloaded from the Protein Data Bank (PDB entry
1SA0: http://www.rcsb.org/pdb/home/home.do) (Ravelli
et al., 2004). Docking studies were performed for proposed
11e in the colchicine-binding site of tubulin. The AutoDock
Vina (The Scripps Research Institute, Molecular Graphics
Lab., La Jolla, CA, USA) was used to perform docking calcu-
lations (Trott and Olson, 2010). The final results were pre-
pared with PyMOL (v. 1.3) (Schrödinger LLC., Shanghai
Office, Shanghai, China) in Windows 7. After removing the
ligand and solvent molecules, hydrogen atoms were added to
each amino acid atom. The three-dimensional structure of
compound were obtained from ChemBioDraw ultra 12.0
(PerkinElmer Inc., Waltham, MA, USA) followed by MM2
energy minimization. Docking was carried out by AutoDock
Vina in the colchicine-binding pocket. Grid map in Auto-
Dock 4.0 was used to define the interaction of protein and
ligand in the binding pocket. For compound binding into the
colchicine-binding site, a grid box size of 25 × 25 × 25 points
in x, y and z directions was built and the grid centre was
located in x = 116.909, y = 89.688 and z = 7.904.
Localization of microtubules
After treatment, cells were fixed with 4% PFA in PBS, blocked
with 2% BSA, stained with anti-tubulin monoclonal anti-
body, and then with FITC conjugated anti-mouse IgG anti-
body. PI was used to stain the nuclei. Cells were visualized
using a Leica TCS SP2 Spectral Confocal System (Leica
Microsystems GmbH).
Mitochondrial membrane potential analysis
Cells were plated (6 well plates) at 1.0 × 106 cells·per well and
treated with 50 nM 11e for 6–24 h. Mitochondrial mem-
branes were stained with 0.5 mL JC-1 working solution (BD
MitoScreen Kit; BD Biosciences Pharmingen, San Diego, CA,
USA) added to each sample. Samples were incubated for
10–15 min at 37°C in the dark. Mitochondrial membrane
potential was measured using the BD FACSCanto flow cyto-
meter (Becton Dickinson).
Western blot assay
The treated cells (1 × 107 cells·10 mL−1 in 10 cm dish) were
collected and washed with PBS. After centrifugation, cells
were lysed in a lysis buffer. The lysates were incubated on ice
for 30 min and centrifuged at 12 000 g for 20 min. Superna-
tants were collected and protein concentrations were then
determined using the Bradford assay. After adding a 5 ×
sample loading buffer containing 625 mM Tris-HCl, pH = 6.8,
500 mM dithiothreitol, 10% SDS, 0.06% bromophenol blue
and 50% glycerol, protein samples were separated by electro-
phoresis on 10% SDS-polyacrylamide gel and transferred to a
nitrocellulose membrane. Immunoreactivity was detected
using the Western blot chemiluminescence reagent system
(PerkinElmer, Boston, MA, USA).
Statistical analysis
Statistical analysis was performed with ANOVA followed by
Tukey’s test. All data were expressed as mean ± SEM. P < 0.001
was indicative of a significant difference.
Results
Chemistry
The synthetic procedures for the new 4-substituted
benzyloxyquinolin-2(1H)-ones (7a–e ∼ 15a–e) are illustrated
BJPSynthesis and anticancer activity of 2-quinolones
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in Scheme 1. A general synthetic approach to the key inter-
mediate 4-hydroxyquinolin-2(1H)-one is the Knorr quinoline
synthesis, which involves cyclization and dehydration
of a transient β-ketoanilide, formed by condensation of a
β-keto ester and aniline at relatively high temperature.
More specific synthetic approaches include cyclization of
N-acetylanthranilic acid derivatives (Buckle et al., 1975), con-
densation of malonates/malonic acid with anilines using
ZnCl2 and POCl3 (Zhang et al., 2008; Priya et al., 2010), Ph2O
(Ahvale et al., 2008) and cyclization of malonodianilides
with PPA (Cai et al., 1996; Park et al., 2007; Moradi-
e-Rufchahi, 2010), CH3SO3H/P2O5 (Kappe et al., 1988) and
p-toluenesulfonic acid (Nadaraj et al., 2006). In our study,






1a : R1 = R2 = R3 = H
1b : R1 = F , R2 = R3 = H
1c : R1 = Cl , R2 = R3 = H
1d : R1 = CH3 , R
2 = R3 = H
1e : R1 = OCH3 , R
2 = R3 = H
1f : R1 = R3 = H , R2 = OCH3
1g : R1 = R2 = H , R3 = OCH3
1h : R1 = R2 = H , R3 = Cl
1i : R1 = R2 = H , R3 = CH3
2
5a-i
5a : R1 = R2 = R3 = H
5b : R1 = F , R2 = R3 = H
5c : R1 = Cl , R2 = R3 = H
5d : R1 = CH3 , R
2 = R3 = H
5e : R1 = OCH3 , R
2 = R3 = H
5f : R1 = R3 = H , R2 = OCH3
5g : R1 = R2 = H , R3 = OCH3
5h : R1 = R2 = H , R3 = Cl
5i : R1 = R2 = H , R3 = CH3
3a, 4a : R1 = R2 = R3 = H
3b, 4b : R1 = F , R2 = R3 = H
3c, 4c : R1 = Cl , R2 = R3 = H
3d, 4d : R1 = CH3 , R
2 = R3 = H
3e, 4e : R1 = OCH3 , R
2 = R3 = H
3f, 4f : R1 = R3 = H , R2 = OCH3
3g, 4g : R1 = R2 = H , R3 = OCH3
3h, 4h : R1 = R2 = H , R3 = Cl




X = Br or Cl
6a R = H
6b R = 2-OCH3
6c R = 3-OCH3
6d R = 4-OCH3




7a : R1 = R2 = R3 = H ; R = H
7b : R1 = R2 = R3 = H ; R = 2'-OCH3
7c : R1 = R2 = R3 = H ; R = 3'-OCH3
7d : R1 = R2 = R3 = H ; R = 4'-OCH3
7e : R1 = R2 = R3 = H ; R = 3', 5'-(OCH3)2
8a : R1 = F , R2 = R3 = H ; R = H
8b : R1 = F , R2 = R3 = H ; R = 2'-OCH3
8c : R1 = F , R2 = R3 = H ; R = 3'-OCH3
8d : R1 = F , R2 = R3 = H ; R = 4'-OCH3
8e : R1 = F , R2 = R3 = H ; R = 3', 5'-(OCH3)2
9a : R1 = Cl , R2 = R3 = H ; R = H
9b : R1 = Cl , R2 = R3 = H ; R = 2'-OCH3
9c : R1 = Cl , R2 = R3 = H ; R = 3'-OCH3
9d : R1 = Cl , R2 = R3 = H ; R = 4'-OCH3
9e : R1 = Cl , R2 = R3 = H ; R = 3', 5'-(OCH3)2
10a : R1 = CH3 , R
2 = R3 = H ; R = H
10b : R1 = CH3 , R
2 = R3 = H ; R = 2'-OCH3
10c : R1 = CH3 , R
2 = R3 = H ; R = 3'-OCH3
10d : R1 = CH3 , R
2 = R3 = H ; R = 4'-OCH3
10e : R1 = CH3 , R
2 = R3 = H ; R = 3', 5'-(OCH3)2
11a : R1 = OCH3 , R
2 = R3 = H ; R = H
11b : R1 = OCH3 , R
2 = R3 = H ; R = 2'-OCH3
11c : R1 = OCH3 , R
2 = R3 = H ; R = 3'-OCH3
11d : R1 = OCH3 , R
2 = R3 = H ; R = 4'-OCH3
11e : R1 = OCH3 , R
2 = R3 = H ; R = 3', 5'-(OCH3)2
12a : R1 = R3 = H , R2 = OCH3 ; R = H
12b : R1 = R3 = H , R2 = OCH3 ; R = 2'-OCH3
12c : R1 = R3 = H , R2 = OCH3 ; R = 3'-OCH3
12d : R1 = R3 = H , R2 = OCH3 ; R = 4'-OCH3










































13a : R1 = R2 = H , R3 = OCH3 ; R = H
13b : R1 = R2 = H , R3 = OCH3 ; R = 2'-OCH3
13c : R1 = R2 = H , R3 = OCH3 ; R = 3'-OCH3
13d : R1 = R2 = H , R3 = OCH3 ; R = 4'-OCH3
13e : R1 = R2 = H , R3 = OCH3 ; R = 3', 5'-(OCH3)2
14a : R1 = R2 = H , R3 = Cl ; R = H
14b : R1 = R2 = H , R3 = Cl ; R = 2'-OCH3
14c : R1 = R2 = H , R3 = Cl ; R = 3'-OCH3
14d : R1 = R2 = H , R3 = Cl ; R = 4'-OCH3
14e : R1 = R2 = H , R3 = Cl ; R = 3', 5'-(OCH3)2
15a : R1 = R2 = H , R3 = CH3 ; R = H
15b : R1 = R2 = H , R3 = CH3 ; R = 2'-OCH3
15c : R1 = R2 = H , R3 = CH3 ; R = 3'-OCH3
15d : R1 = R2 = H , R3 = CH3 ; R = 4'-OCH3
15e : R1 = R2 = H , R3 = CH3 ; R = 3', 5'-(OCH3)2
Scheme 1
Reagents and conditions: (A) 130°C with PPA. (B) K2CO3/DMF, 80–90°C.
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sized by treatment of a substituted aniline (1a–i) with
diethylmalonate (2) in one flask (Mohamed, 1991; Arya and
Agarwal, 2007), followed by cyclization of the formed mono-
anilide (3a–i) or malondianilide (4a–i) precursors in the
presence of PPA. The target 4-benzyloxyquinolin-2(1H)-one
derivatives 7a–e, 8a–e, 9a–e, 10a–e, 11a–e, 12a–e, 13a–e,
14a–e and 15a–e were synthesized by reaction of the inter-
mediate 4-hydroxyquinolin-2(1H)-one derivatives 5a–i with
various benzyl halide 6a–e in the presence of K2CO3 and
DMF (Guo et al., 2009; Deng et al., 2010). All synthetic prod-
ucts were characterized by IR, 1H and 13C NMR and mass
spectroscopy.
The 2-quinolones have a minor tautomeric structure
(2-hydroxyquinoline) because of protonation of the
carbonyl oxygen (Lewis et al., 1991). Deprotonation of the
2-quinolone would cause ring resonance and electron
shifting within the N-1, O-2, C-3 and O-4 positions of
the 4-hydroxyquinolin-2(1H)-one derivatives (Figure 2A)
(Pirrung and Blume, 1999). Consequently, earlier reports
have indicated that 4-hydroxyquinolin-2(1H)-ones could be
alkylated at the 1-NH, 2-OH, 4-OH or 3-CH position (Park and
Lee, 2004; Ahmed et al., 2010; 2011). Therefore, we con-
firmed the structures of our synthesized compounds using
NMR spectroscopic analyses. The 1H NMR spectrum of
4-benzyloxyquinolin-2(1H)-one derivatives 7a–e ∼ 15a–e
featured a singlet for O-linked C(9)-H2 methylene protons
between 5.13 and 5.27 ppm, a singlet for a C(3)-H proton
between 5.80 and 6.09 ppm and a broad singlet for an
exchangeable NH group between 10.47 and 11.54 ppm. The
chemical shifts for the benzylic CH2 were consistent with
O-alkylation rather than N-alkylation (Park and Lee, 2004).
The 13C shifts for O-alkylated compounds are typically
downfield (higher ppm value; 52.7–68.4) compared with
N-alkylated compounds (lower ppm value; 28.6–45.0)
(LaPlante et al., 2013). The 13C NMR spectra of 7a–e ∼ 15a–e
included an O-linked methylene carbon between 65.74 and
70.74 ppm, which again indicated O-alkylation. Furthermore,
regioselective alkylation at the 4-OH position was confirmed
by two-dimensional NMR study via heteronuclear multiple-
quantum correlation and heteronuclear multiple-bond corre-
lation (HMBC) spectroscopy experiments that disclose the
relationship between 1H and 13C coupling. In the case of
compound 11e, as shown in Figure 2B, the 4-O-linkage was
supported by observation of 3J-HMBC correlations between
C(9)-H methylene protons (δH 5.20) on the 3′,5′-
dimethoxybenzyloxy moiety with the carbon at C(4) position
(δc 161.89) of the 2-quinolone core, which shows a further
correlation with the C(5)-H proton (δH 7.14–7.26, over-
lapped). In other words, O4-alkylation was determined
through the observation of H9/C4 and H5/C4 cross-peaks.
These data proved that 3′,5′-dimethoxybenzyloxy moiety is
attached to the 4-O-position of the 2-quinolone core struc-
ture. Furthermore, the IR spectra of 7a–e ∼ 15a–e possessed a
characteristic absorption band for an amido C = O group
(1633–1674 cm–1).
Biological evaluation and SAR analysis
All newly synthesized target compounds (7a–e, 8a–e, 9a–e,
10a–e, 11a–e, 12a–e, 13a–e, 14a–e and 15a–e) were
assayed for growth inhibitory activity against Detroit 551
cells (human normal skin fibroblast) and four cancer cell lines
– HL-60 (leukaemia), Hep 3B (hepatoma), H460 (non-small-
cell lung carcinoma) and COLO 205 (colorectal adenocarci-
noma). Cells were treated with compounds for 48 h and cell
proliferation was determined by MTT assay. The antiprolif-
erative activity of each compound was presented as the con-
centration of compound that achieved 50% inhibition (IC50)
of cancer cell growth. The results are summarized in Table 1.
Collectively, the present series of novel 4-benzyloxyquinolin-
2(1H)-one derivatives exhibited a range of potencies against
the four tested tumour cell lines. Among them, compounds
7e, 8e, 9b, 9c, 9e, 10c, 10e, 11c and 11e displayed high
potency against HL-60, Hep3B, H460 and COLO 205 cells,
with IC50 value less than 1 μM (Table 1). Notably, 11e dis-
played the most prominent growth inhibitory activities
against these four cell lines with IC50 values ranging from 14
to 40 nM. Moreover, none of the active compounds showed
cytotoxicity (IC50 > 50 μM) towards Detroit 551 cells. These
results suggested that this new series of 4-benzyloxyquinolin-
2(1H)-one derivatives could effectively suppress tumour
growth without causing toxicity to normal somatic cells.
Based on the biological data obtained so far, SAR correla-
tions were determined. Firstly, we evaluated the effects of
Figure 2
Alkylation of 4-hydroxyquinolin-2(1H)-ones. (A) Tautomerism of 4-hydroxyquinolin-2(1H)-one derivatives. (B) Key HMBC correlations (blue
arrows) of 11e indicated alkylation at the 4-OH position.
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Table 1
Antiproliferative effects of compounds 7a–e ∼ 15a–e
Compound R1 R2 R3 R
IC50 (μM)a
HL-60b Hep 3Bb H460b COLO205b Detroit 551b
7a H H H H >50 >50 >50 >50 >50
7b H H H 2′-OCH3 >50 >50 >50 >50 >50
7c H H H 3′-OCH3 16.4 >50 >50 7.5 >50
7d H H H 4′-OCH3 >50 >50 >50 >50 >50
7e H H H 3′, 5′-(OCH3)2 0.68 0.64 0.69 0.42 >50
8a F H H H >50 >50 >50 >50 >50
8b F H H 2′-OCH3 8.7 >50 >50 7.3 >50
8c F H H 3′-OCH3 >50 >50 >50 50 >50
8d F H H 4′-OCH3 >50 >50 >50 >50 >50
8e F H H 3′, 5′-(OCH3)2 0.4 0.9 0.6 0.39 >50
9a Cl H H H 4.5 >50 >50 9.8 >50
9b Cl H H 2′-OCH3 0.6 2.2 2.8 0.41 >50
9c Cl H H 3′-OCH3 0.3 0.8 1.0 0.35 >50
9d Cl H H 4′-OCH3 >50 >50 >50 >50 >50
9e Cl H H 3′, 5′-(OCH3)2 0.0295 0.15 0.19 0.054 >50
10a CH3 H H H – >50 >50 8.2 –
10b CH3 H H 2′-OCH3 – 1.8 1.7 1.0 –
10c CH3 H H 3′-OCH3 – 0.68 0.89 0.36 –
10d CH3 H H 4′-OCH3 – >50 >50 >50 –
10e CH3 H H 3′, 5′-(OCH3)2 – 0.54 0.27 0.06 –
11a OCH3 H H H 8.5 27.0 51.7 8.8 >50
11b OCH3 H H 2′-OCH3 1.5 4.3 3.3 5.0 >50
11c OCH3 H H 3′-OCH3 0.2 0.9 0.6 0.21 >50
11d OCH3 H H 4′-OCH3 >50 >50 >50 >50 >50
11e OCH3 H H 3′, 5′-(OCH3)2 0.014 0.035 0.04 0.028 >50
12a H OCH3 H H – 9.55 17.3 14.2 –
12b H OCH3 H 2′-OCH3 – 4.02 7.1 6.4 –
12c H OCH3 H 3′-OCH3 – 3.23 >50 8.2 –
12d H OCH3 H 4′-OCH3 – >50 >50 >50 –
12e H OCH3 H 3′, 5′-(OCH3)2 – 2.11 3.96 4.9 –
13a H H OCH3 H >50 >50 >50 34.1 >50
13b H H OCH3 2′-OCH3 >50 >50 >50 >50 >50
13c H H OCH3 3′-OCH3 20.0 39.9 32.3 22.6 >50
13d H H OCH3 4′-OCH3 >50 >50 >50 >50 >50
13e H H OCH3 3′, 5′-(OCH3)2 3.3 3.8 2.2 2.6 >50
14a H H Cl H – >50 >50 >50 –
14b H H Cl 2′-OCH3 – >50 >50 >50 –
14c H H Cl 3′-OCH3 – >50 >50 >50 –
14d H H Cl 4′-OCH3 – >50 >50 >50 –
14e H H Cl 3′, 5′-(OCH3)2 – 3.64 19.4 9.7 –
15a H H CH3 H >50 >50 >50 >50 >50
15b H H CH3 2′-OCH3 20.0 >50 >50 41.5 >50
15c H H CH3 3′-OCH3 >50 >50 >50 >50 >50
15d H H CH3 4′-OCH3 10.0 >50 >50 >50 >50
15e H H CH3 3′, 5′-(OCH3)2 0.72 2.0 3.3 2.6 >50
Etoposide 5.48 – 1.0 – –
aHuman tumour cells were treated with different concentrations of samples for 48 h. Data are presented as IC50 (μM, the concentration of 50% proliferation-
inhibitory effect). bCell lines include leukaemia (HL-60), liver carcinoma (Hep3B), lung carcinoma (H460), colon carcinoma (COLO205) and normal skin fibroblasts
(Detroit 551).
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methoxy substitution of the C-4 benzyloxy ring (C ring) on
the cytotoxic activity. Generally, compounds with 3′,5′-
dimethoxybenzyloxy side chain (7e–15e) showed the
highest potency in their respective series (7–15). Among
them, compounds 7e, 8e, 9e, 10e and 11e exhibited signifi-
cant activity against Hep 3B, H460 and COLO 205 cancer cell
lines (IC50 < 1 μM). These results indicated 3′,5′-dimethoxy-
benzyloxy substitution is preferred relative to other benzyl
substitution. Compounds 9b, 9c, 10b, 10c, 11b, 11c with a
2′- or 3′-methoxybenzyloxy side chain demonstrated moder-
ate activity (IC50 0.2–5.0 μM), whereas compounds bearing
side chains of benzyloxy or 4′-methoxybenzyloxy were inac-
tive (IC50 > 50 μM) or exhibited only marginal activity (IC50
4.5–10 μM).
Next, we explored the SAR of the 2-quinolone A ring.
Compounds with a substituted benzyloxy moiety at C-4 and
various functional groups at C-6, -7 and -8 were studied and
different anticancer effects were found. Regarding the C-6
substitution, compound 8e (6-fluoro), 9e (6-chloro), 10e
(6-methyl) and 11e (6-methoxy) were more potent than 7e
(no substitution). Moreover, compound 11e (IC50 0.014–
0.04 μM) displayed the strongest growth inhibitory activity
among the C-6 substituted compounds, suggesting that the
C-6 methoxy group might play a pivotal role. Moving the
methoxy group from C-6 to C-7 (12e, IC50 2.11–4.9 μM) or
C-8 (13e, IC50 2.2–3.8 μM) dramatically decreased inhibitory
activity. Activity also decreased when the C-8 methoxy of 13e
was replaced with chlorine (14e), while activity was retained
when the methoxy was replaced with methyl (15e). Thus, in
this series of 4-benzyloxy-2-quinolones, optimal antiprolif-
erative effects were found with a 6-methoxy group on the
2-quinolone ring.
In the present work, the earlier findings can be summa-
rized in the following two SAR conclusions:
(i) The in vitro anticancer activity of the substituted benzy-
loxy moiety (C ring) on the 4-position of 2-quinolone
derivatives can be ranked in the following order of
decreasing activity: 3′,5′-dimethoxybenzyloxy (7e–15e) >
3′-methoxybenzyloxy (7c–15c) ≧ 2′-methoxybenzyloxy
(7b–15b) > benzyloxy (7a–15a) ≧ 4′-methoxybenzyloxy
(7d–15d).
(ii) C-6 substituents on the 2-quinolone (A ring) resulted in
better activity compared with C-7 and C-8 substituent.
The following rank order of in vitro anticancer activity
was found relative to the identity of the C-6 substituent:
6-methoxy > 6-chloro ≧ 6-methyl > 6-fluoro ≧ no
substitution.
Anticancer drug screen panel of compound
9b, 9c, 9e and 11e against NCI-60 human
cancer cell lines
We selected four potent compounds 9b, 9c, 9e and 11e and
submitted them for screening against the NCI-60 HTCL panel
assay through the US NCI DTP (Boyd and Paull, 1995;
Shoemaker, 2006). The cell lines used in this assay represent
nine tumour subpanels, leukaemia, melanoma and cancers of
lung, colon, brain (CNS), ovary, kidney, prostate and breast.
Initially, the compounds were added at a single dose (10 μM)
and the culture was incubated for 48 h. End-point determi-
nations were made with a sulforhodamine B assay. Results for
each compound are given in Table 2, with a negative value in
the cell growth percentage indicating an antiproliferative
effect against that cell line. Compound 9b displayed positive
cytotoxic effects towards 11 out of 60 cell lines, and the
positive cytotoxic proportions of 9c, 9e and 11e were 10/59,
18/60 and 26/57. Our prominent compound 11e exhibited
inhibitory effects ranging from –59% to −0.80%. At the
primary single high dose 10 μM (10−5 M), 9b, 9c, 9e and 11e
showed greatest effects against colon carcinoma COLO 205
with cell growth percentage of −55, −57, −64 and −59 respec-
tively. The melanoma MDA-MB-435 cell line was also sensi-
tive to these compounds (growth percentages −46%, −43%,
−43% and −41% respectively).
At the second evaluation stage, the selected compounds
were evaluated at five different concentrations (0.01, 0.1, 1,
10 and 100 μM) against the same NCI-60 HTCL panel. The
outcomes were represented by three calculated response
parameters (GI50, TGI and LC50) for each cell line through
growth percentage inhibition curves (Holbeck, 2004; Holbeck
et al., 2010). The GI50 value (growth inhibitory activity) cor-
responds to the concentration of compound causing 50%
decrease in net cell growth, the TGI value (cytostatic activity)
is the concentration of compound resulting in total growth
inhibition (100% growth inhibition) and LC50 value (cyto-
toxic activity) is the lethal dose of compound causing net
50% death of initial cells. The calculated results are presented
as log concentration (given in the Supporting Information),
as shown in Table 3. The NCI data revealed broad-spectrum
sensitivity profiles for 9b, 9c, 9e and 11e towards all nine
cancer subpanels with GI50 values less than 1 μM, and less
than 0.01 μM (log GI50 < −8.0) against some cell lines for 9e
and 11e. The anticancer effects of these compounds were
comparable with those of fluorouracil (5-FU), which is widely
used clinically for treating cancer (Longley et al., 2003). These
screening results were in good agreement with the single dose
results, showing broad anticancer spectra for 9b, 9c, 9e and
11e. Notably, compound 11e exhibited GI50 values ranging
from 0.01 to 8.08 μM in 51 of the 56 cell lines, with GI50
values below 0.01 μM in five cell lines (leukaemia K-562 and
SR, non-small-cell lung cancer NCI-H522, colon cancer
COLO 205, melanoma MDA-MB-435).
To further determine which cancer subtypes were more
sensitive to these 4-benzyloxy-2-quinolones, we calculated
subpanel-selectivity ratios based upon GI50 values. The calcu-
lated results are shown in Table 4 and Figure 3. Selectivity
ratios less than 3 were rated non-selective, ratios ranging
from 3 to 6 were termed moderately selective and ratios
greater than 6 were designated highly selective (Boyd and
Paull, 1995; Noolvi et al., 2012; Chen et al., 2013a). With all
ratios less than 3, compounds 9b and 9c were rated non-
selective towards all nine subpanels. Interestingly, both 9e
and 11e, which contain a 3′,5′-dimethoxybenzyloxy moiety,
were much more selective than 9b and 9c (Figure 3). As
shown in Table 4, the average selectivity ratios of 9e and 11e
(ratios = 6.51 and 4.05) were higher than those of 9b and 9c
(ratios = 1.12 and 1.28). Compound 9e exhibited selectivity
against leukaemia, colon cancer, CNS cancer, melanoma,
renal cancer and prostate cancer. In terms of the total MID
(an average sensitivity across all cell lines), compound 11e
displayed significant activity (0.31 μM) and was moderately
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Table 2
Growth percentages of selected compounds in the NCI in vitro 60-cell Drug Screen Program
Panel/Cell line
Compounds/Growth percentage (%)a
9b 9c 9e 11e
Leukaemia
CCRF-CEM 18.56 11.98 15.94 −26.21b
HL-60(TB) 9.64 −9.34 7.37 −32.61
K-562 15.80 17.65 11.80 3.56
MOLT-4 39.79 38.04 42.35 4.78
RPMI-8226 19.77 17.87 15.90 −6.67
SR 14.68 5.97 7.02 −4.86
Non-small-cell lung cancer
A549/ATCC 29.44 21.67 −22.24 7.15
EKVX 50.93 41.72 52.28 –
HOP-62 −18.38 −22.55 −27.19 24.70
HOP-92 19.45 46.83 43.66 28.92
NCI-H226 42.44 48.35 8.57 54.52
NCI-H23 32.69 33.31 3.47 −47.65
NCI-H322M 36.63 35.35 39.53 21.59
NCI-H460 10.03 5.68 2.71 3.87
NCI-H522 18.21 22.30 −0.77 −29.70
Colon cancer
COLO 205 −55.40 −57.40 −64.41 −59.50
HCC-2998 23.46 27.86 −12.73 −32.77
HCT-116 25.11 28.76 3.95 0.12
HCT-15 24.78 19.69 17.60 7.24
HT-29 7.13 2.57 0.32 −27.36
KM12 30.65 22.39 10.66 1.77
SW-620 12.10 21.07 20.17 10.28
CNS cancer
SF-268 42.91 42.47 27.59 8.61
SF-295 6.76 9.92 −2.30 −3.44
SF-539 5.03 −2.10 −35.52 −28.70
SNB-19 28.95 30.82 19.73 48.02
SNB-75 −22.87 −16.82 −42.27 –
U251 16.38 18.14 −21.80 5.44
Melanoma
LOX IMVI 14.48 17.90 2.15 −6.75
MALME-3M 45.00 31.84 32.02 55.33
M14 13.96 19.46 8.30 −50.76
MDA-MB-435 −46.28 −43.14 −43.16 −41.44
SK-MEL-2 23.93 5.30 10.59 −14.08
SK-MEL-28 −12.04 4.07 −8.81 7.02
SK-MEL-5 −25.75 −32.70 0.36 −27.48
UACC-257 24.32 21.96 19.86 34.86
UACC-62 −19.98 4.59 5.49 −48.21
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selective towards the breast cancer subpanel and highly selec-
tive against leukaemia, colon cancer and prostate cancer.
Among the subpanels rated highly selective, colon cancer
was extremely sensitive to compound 11e (NSC 764592;
Figure 3). This compound showed exceptional potency
against the individual cell line COLO 205 (LC50 0.09 μM, TGI
0.03 μM) (Table 3). From the dose-response curves against six
colon cancer cell lines (Figure 4), it is also obvious that 11e
exhibited particular selectivity against COLO 205.
Morphological changes and apoptosis in
COLO 205 cells induced by compound 11e
Based on the in vitro cytotoxicity data, 11e (NSC 764592), the
most potent compound against COLO 205 cells was selected
for further biological studies. Apoptosis is well known as a
process of programmed cell death (Elmore, 2007). In our
previous study, 4-phenyl-2-quinolone analogues (4-PQs)





9b 9c 9e 11e
Ovarian cancer
IGROV1 45.21 39.68 46.14 –
OVCAR-3 4.64 6.22 −59.96 −32.89
OVCAR-4 34.25 42.73 29.48 40.39
OVCAR-5 48.30 36.30 32.38 18.06
OVCAR-8 33.86 24.06 6.15 9.94
NCI/ADR-RES 19.48 20.52 3.42 −14.04
SK-OV-3 −17.68 −27.16 −27.00 −0.80
Renal cancer
786-0 33.73 39.62 3.94 −2.61
A498 21.88 16.02 −2.40 −8.21
ACHN 44.36 43.14 23.77 19.79
CAKI-1 31.23 30.29 27.34 9.52
RXF 393 −14.00 – −25.73 −11.48
SN12C 27.70 32.18 16.82 2.52
TK-10 50.99 41.50 −2.79 18.32
UO-31 38.23 34.68 28.46 30.52
Prostate cancer
PC-3 21.26 23.95 27.74 20.50
DU-145 16.06 14.85 20.65 1.31
Breast cancer
MCF7 −5.90 1.34 −35.96 13.94
MDA-MB-231/ATCC 29.63 40.04 5.25 −2.71
HS 578T 9.12 21.68 21.06 31.90
BT-549 42.21 48.16 30.87 −19.04
T-47D −19.71 −16.85 21.81 50.59
MDA-MB-468 24.05 −25.33 −23.96 −4.24
Mean growth 17.02 16.59 5.26 0.19
Range of growth −55.40 to 50.99 −57.40 to 48.35 −64.41 to 52.28 −59.50 to 55.33








Positive cytostatic effectc 47/60 49/59 41/60 28/57
Positive cytotoxic effectd 11/60 10/59 18/60 26/57
aData obtained from NCI in vitro 60-cell screen programme at 10 μM. bNegative values represent compound proved lethal to the cancer cell
line (cell death). cRatio between number of cell lines with percentage growth from 0 to 50 and total number of cell lines. dRatio between
number of cell lines with percentage growth of <0 and total number of cell lines. The bold values indicate significant cytotoxicity toward
cancer cell lines.
BJPSynthesis and anticancer activity of 2-quinolones
British Journal of Pharmacology (2015) 172 1195–1221 1205
Table 3
In vitro antitumour activity (GI50 in μM), toxicity (LC50 in μM) and TGI data of selected compounds 9b, 9c, 9e and 11e
Panel/Cell line
Compoundsa
9b 9c 9e 11e 5-FUb
GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50
Leukaemia
CCRF-CEM 0.39 19.50 >100 0.31 >100 >100 0.04 >100 >100 0.03 >100 >100 10.00 >100 >100
HL-60(TB) – – – – – – – – – 0.04 >100 >100 2.51 >100 >100
K-562 0.08 11.60 92.50 0.03 – >100 <0.01 1.67 >100 <0.01 >100 >100 3.98 >100 >100
MOLT-4 0.51 32.50 >100 0.33 >100 >100 0.05 >100 >100 0.07 >100 >100 0.32 50.12 >100
RPMI-8226 0.61 21.40 >100 0.43 >100 >100 0.08 >100 >100 0.03 >100 >100 0.05 50.12 >100
SR 0.20 0.89 >100 0.03 0.95 >100 <0.01 0.08 >100 <0.01 >100 >100 0.03 10.00 >100
Non-small-cell
lung cancer
A549/ATCC – – – – – – – – – 0.02 >100 >100 0.20 63.10 >100
EKVX 0.46 40.70 >100 0.22 >100 >100 0.24 >100 >100 – – – 63.10 >100 >100
HOP-62 0.53 2.82 17.80 0.33 – >100 0.04 14.10 43.30 0.03 12.20 75.10 0.40 >100 >100
HOP-92 1.09 5.18 31.80 1.42 >100 >100 11.90 >100 >100 0.02 10.80 >100 79.43 >100 >100
NCI-H226 2.24 41.00 >100 3.25 >100 >100 10.20 >100 >100 2.80 >100 >100 50.12 >100 >100
NCI-H23 0.93 12.00 69.40 0.51 >100 >100 0.08 63.80 >100 0.07 13.30 >100 0.32 39.81 >100
NCI-H322M 0.57 9.76 >100 0.36 >100 >100 0.05 >100 >100 0.08 >100 >100 0.20 7.94 >100
NCI-H460 0.39 3.87 37.10 0.05 – >100 0.03 23.90 >100 0.03 >100 >100 0.06 50.12 >100
NCI-H522 0.15 0.46 6.55 0.03 0.19 12.30 <0.01 0.03 0.10 <0.01 0.03 >100 7.94 63.10 >100
Colon cancer
COLO 205 0.39 2.45 60.80 0.22 1.89 >100 0.03 0.10 2.48 <0.01 0.03 0.09 0.16 63.10 >100
HCC-2998 1.04 12.40 61.10 0.30 >100 >100 0.12 31.60 >100 0.05 1.98 >100 0.05 39.81 >100
HCT-116 0.42 1.74 6.74 0.11 – – 0.04 >100 >100 0.04 10.40 >100 0.25 3.98 25.12
HCT-15 0.54 >100 >100 0.29 >100 >100 0.04 >100 >100 0.03 18.90 >100 0.10 50.12 >100
HT-29 0.30 0.85 11.50 0.04 0.41 – 0.03 0.08 >100 0.01 – >100 0.16 63.10 >100
KM12 0.53 18.10 >100 0.06 >100 >100 0.04 >100 >100 0.03 3.18 >100 0.20 39.81 >100
SW-620 0.39 12.50 >100 0.05 >100 >100 0.03 >100 >100 0.02 >100 >100 1.00 >100 >100
CNS cancer
SF-268 0.68 20.60 >100 0.49 >100 >100 0.05 75.20 >100 1.08 >100 >100 1.58 >100 >100
SF-295 0.24 0.74 5.10 0.09 0.77 4.63 0.02 0.08 24.90 – – – 0.25 3.98 >100
SF-539 0.60 2.77 14.00 0.39 2.21 >100 0.04 1.20 >100 0.03 0.21 58.70 0.06 79.43 >100
SNB-19 0.58 14.30 >100 0.41 4.49 >100 0.06 28.30 >100 0.09 >100 >100 3.98 79.43 >100
SNB-75 0.30 1.40 14.80 0.24 0.95 13.50 0.03 0.09 36.90 0.01 0.05 26.70 79.43 >100 >100
U251 0.45 10.50 46.80 0.42 3.57 >100 0.05 16.00 56.60 0.04 12.00 >100 1.00 79.43 >100
Melanoma
LOX IMVI 0.59 3.58 32.70 0.51 2.78 >100 0.07 >100 >100 0.06 10.30 >100 0.25 50.12 79.43
MALME-3M 0.32 10.30 >100 0.11 >100 >100 0.03 54.30 >100 – >100 >100 0.05 2.51 >100
M14 0.32 1.11 57.90 0.14 1.25 >100 0.04 2.07 >100 0.04 0.26 4.29 1.00 >100 >100
MDA-MB-435 0.06 0.24 0.73 0.02 0.04 0.09 <0.01 0.02 0.08 <0.01 0.02 2.68 0.08 79.43 >100
SK-MEL-2 0.34 0.86 25.40 0.15 0.74 >100 0.02 0.06 27.20 – >100 >100 63.10 >100 >100
SK-MEL-28 0.71 12.70 >100 0.47 >100 >100 0.07 >100 >100 0.07 >100 >100 1.00 63.10 >100
SK-MEL-5 0.26 – 54.70 0.19 – >100 0.03 >100 >100 0.02 1.85 7.08 0.50 39.81 79.43
UACC-257 – >100 >100 – >100 >100 – >100 >100 8.08 >100 >100 3.98 79.43 >100
UACC-62 0.45 4.25 30.80 0.35 8.90 >100 0.04 51.60 >100 0.03 >100 >100 0.50 39.81 >100
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H460 cells (Chen et al., 2013b). In order to characterize the
cellular basis for the antiproliferative effects of the selected
derivative 11e, we investigated the ability of this compound
to induce apoptosis in COLO 205 cells. Morphological analy-
sis confirmed the cytotoxic effects of 11e in COLO 205 cells.
As shown in Figure 5A, the apoptotic morphological changes
included cell rounding and shrinkage after 24 h incubation
with 50 nM of 11e (the black arrowhead indicates an apop-
totic nucleus). To confirm the induction of apoptosis by 11e,
COLO 205 cells were stained with Hoechst 33258, a fluores-
cent DNA-staining dye, and cell morphology was investigated
using fluorescence microscopy. As shown in Figure 5B,
control cells exhibited uniformly dispersed chromatin,
homogeneous blue fluorescence in the nuclei, normal orga-
nelles and intact cell membranes. In cells treated with 50 nM
of 11e for 24, 36 and 48 h, the nuclei budded off into several
fragments and nuclear condensation and fragmentation were
observed (Figure 5B), indicating typical characteristics of apo-
ptosis, including condensation of chromatin, shrinkage of
nuclei and appearance of apoptotic bodies (the black arrow-
head indicates an apoptotic nucleus).
Annexin V-FITC/PI double-labelling was used to detect
phosphatidylserine externalization, a characteristic effect of
apoptosis (van Engeland et al., 1998; Zhuang et al., 2013). In
Figure 5C, populations of viable (annexin V–, PI–), early apo-
ptotic (annexin V+, PI–), late apoptotic (annexin V+ , PI+) and
necrotic (annexin V–, PI+) cells are found in quadrants (Q) 3,
4, 2 and 1 respectively. Cells incubated in the absence of 11e
were undamaged and did not stain for annexin V-FITC and PI
(Q3). After incubation with 50 nM of 11e, the number of
early apoptotic cells stained positive by annexin V-FITC and
negative with PI (Q4) increased significantly with incubation
time, from 5.5% (control) to 7.7% after 12 h, 12.7% after





9b 9c 9e 11e 5-FUb
GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50
Ovarian cancer
IGROV1 0.56 6.57 48.60 0.35 >100 >100 0.06 64.80 >100 0.42 >100 >100 1.26 31.62 >100
OVCAR-3 0.38 1.36 7.54 0.24 1.17 5.06 0.02 0.07 7.79 0.02 0.07 28.60 0.02 0.32 50.12
OVCAR-4 2.77 39.80 >100 0.96 >100 >100 0.83 >100 >100 1.11 >100 >100 3.98 79.43 >100
OVCAR-5 2.01 22.80 >100 1.90 >100 >100 0.32 >100 >100 0.09 69.50 >100 10.00 50.12 >100
OVCAR-8 0.48 13.20 57.00 0.43 >100 >100 0.06 28.30 >100 0.05 >100 >100 1.58 31.62 >100
NCI/ADR-RES 0.37 8.09 79.50 0.08 – >100 0.03 11.70 >100 0.01 24.60 >100 0.32 12.59 >100
SK-OV-3 0.50 2.30 11.70 0.35 2.10 >100 0.03 1.04 96.90 0.03 0.93 64.20 19.95 63.10 >100
Renal cancer
786-0 0.62 2.51 8.27 0.58 – >100 0.07 32.30 >100 1.15 11.40 >100 0.79 50.12 >100
A498 0.45 1.87 6.10 0.16 1.88 >100 0.03 22.30 >100 0.02 0.09 78.10 0.40 >100 >100
ACHN 0.73 4.47 31.40 0.61 >100 >100 0.06 >100 >100 0.08 >100 >100 0.32 31.62 >100
CAKI-1 0.32 3.55 52.50 0.06 – >100 0.03 >100 >100 0.02 >100 >100 0.08 2.00 >100
RXF 393 0.47 2.58 13.70 0.41 3.14 >100 0.05 0.31 36.30 0.02 0.08 >100 2.51 31.62 >100
SN12C 0.67 20.80 >100 0.67 >100 >100 0.10 >100 >100 0.09 >100 >100 0.50 25.12 >100
TK-10 – – – – – – – – – 1.05 75.80 >100 1.26 79.43 >100
UO-31 0.39 2.36 15.50 0.16 >100 >100 0.04 >100 >100 0.08 >100 >100 1.58 50.12 >100
Prostate cancer
PC-3 0.89 24.10 >100 0.71 >100 >100 0.06 >100 >100 0.02 >100 >100 2.51 >100 >100
DU-145 0.56 13.70 >100 0.33 – >100 0.04 29.30 >100 0.04 16.00 >100 0.40 >100 >100
Breast cancer
MCF7 0.57 12.30 78.90 0.32 >100 >100 0.21 >100 >100 0.03 >100 >100 0.08 50.12 >100
MDA-MB-231/ATCC 0.92 10.10 58.50 1.29 >100 >100 0.15 55.50 >100 0.15 26.20 >100 6.31 39.81 >100
HS 578T 0.57 5.97 >100 0.30 2.89 >100 0.03 16.80 >100 0.02 100 >100 10.00 >100 >100
BT-549 0.74 19.60 >100 0.65 >100 >100 – 60.00 >100 0.20 9.26 >100 10.00 >100 >100
T-47D 0.51 7.23 38.20 0.38 >100 >100 – >100 >100 0.04 >100 >100 7.94 50.12 >100
MDA-MB-468 1.73 6.13 29.70 0.29 1.03 >100 0.21 0.61 >100 0.05 0.41 >100 – – –
aData obtained from NCI’s in vitro disease-oriented human tumour cell lines screen. bNCI data for 5-FU: NSC 19893. (NCI Anticancer
Screening Program; http://dtp.nci.nih.gov/docs/cancer/searches/standard_mechanism_list.html).
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number of late apoptotic cells stained positive by annexin
V-FITC and PI (Q2) also increased with incubation time, from
9.9% (control) to 10.2% after 12 h, 10.4% after 24 h, 8.6%
after 36 h and 16.1% after 48 h incubation. Thus, when
COLO 205 cells were stained with annexin-V/PI and analysed
with flow cytometry, early and late apoptotic (annexin-V-
stained) cells increased in a time-dependent manner
(Figure 5C), which indicates that 11e can induce apoptosis.
Toxicity in COLO 205 cells induced by 11e
Exposure of COLO 205 cells to 11e for 48 h, followed by MTT
metabolism assays, showed that 11e reduced COLO 205 cell
viability in a dose-dependent manner with an IC50 value of
27.2 ± 1.4 nM (Figure 6B). Inhibition of COLO 205 cell
growth was also dependent of the time of exposure (24-72h)
(Figure 6C).
11e induced apoptotic cell death and
interfered with cell cycle distribution in G2/M
phase arrest
COLO 205 cells were treated with 50 nM of 11e for 0, 6, 12,
24, 36 and 48 h, followed by flow cytometry analysis to
determine the cell cycle distribution of treated cells, as well as
to investigate the 11e-induced inhibition of COLO 205 cell
growth by cell cycle arrest and apoptotic mechanisms. As
shown in Figure 7A, 11e induced a time-dependent accumu-
lation of cells at the G2/M phase.
11e inhibits microtubule polymerization in
COLO 205 cells
COLO 205 cells were treated with 11e (50 nM) for 24 h and
then visualized using confocal microscopy to investigate
effects on microtubule function. As shown in Figure 7B, treat-
ment with 11e resulted in microtubule changes similar to
those induced by colchicine. Both compounds caused cellular
microtubule depolymerization with short microtubule frag-
ments scattered throughout the cytoplasm. In contrast,
another anti-cancer drug, taxol, significantly increased
tubulin polymerization.
Figure 3
Subpanel tumour cell lines selectivity ratios of selected compounds 9b, 9c, 9e and 11e.
Figure 4
Dose-response curves of compound 11e against colon cancer cell
lines.
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Molecular modelling and computational studies
Using a molecular docking method and molecular mode of
tubulin and DAMA-colchicine, 11e was docked into the
colchicine-binding domain of tubulin. As shown in Figure 8A
and B, 11e inserted deeply into the colchicine-binding
pocket of α- and β-tubulin, very similar to the binding mode
of DAMA-colchicine. Superimposition of compounds in the
colchicine-binding site indicated that ring C and ring A are
comparable pharmacophores between DAMA-colchicine and
11e (Figure 8C and D). As shown in Figure 8D, the 1-NH
group of 11e overlapped with the acetamide-NH group of
DAMA-colchicine. Moreover, the 1-NH of 11e formed a
hydrogen bond with Thr179α as was also observed with the
acetamide-NH group of DAMA-colchicine. The -O-CH2- group
of 11e occupied a region in space in proximity to the C5 and
C6 positions in the B-ring of DAMA-colchicine and was
involved in hydrophobic interactions with Lys254β, Ala250β
and Leu248β. The 3′,5′-dimethoxy of 11e overlapped with the
1,3-dimethoxy moiety in the C ring of DAMA-colchicine, the
C ring was involved in hydrophobic interactions with
Leu255β. Finally, the quinolin-2(1H)-one scaffold of 11e partly
overlapped with the A ring of DAMA-colchicine and formed
hydrophobic interactions with Asn258β and Lys352β.
11e changes the expression and
phosphorylation status of G2/M regulatory
proteins in COLO 205 cells
Analysis of cell cycle-related protein expression explored the
mechanisms by which 11e induces G2/M arrest. Firstly,
COLO 205 cells treated with 50 nM of 11e showed increased
cyclin B1 and CDK1 protein levels, which are markers for
induction of mitotic arrest (Figure 9A). Secondly, given the
importance of the aurora kinases in cancer cell mitosis and
metastasis, the effects of 11e (50 nM in COLO 205 cells) on
aurora kinase function were investigated. As shown in
Figure 9B, 11e decreased aurora A, phospho-aurora A, aurora
B and phospho-aurora B expression. Thirdly, we examined
whether 11e inhibited phosphorylation of histone H3 in
COLO 205 cells. Histone H3 is a substrate for aurora B kinase.
During mitosis, aurora B is required for phosphorylation of
histone H3 on Ser10, which might be important for chromo-
some condensation (Keen and Taylor, 2004). As shown by
Western blot analysis, 11e decreased phospho-H3 expression
after a 6 h treatment (Figure 9B). This finding suggests that
inactivation of aurora kinases A and B is involved in 11e-
induced G2/M arrest.
Figure 5
Compound 11e induced time-dependent apoptosis in COLO 205 cells. COLO 205 cells were treated with 50 nM of 11e for 0, 12, 24, 36 and
48 h. (A) Compound 11e induced morphological changes in COLO 205 cells. (B) Fluorescent images of Hoechst staining showing 11e-induced
cell death. The black arrowhead indicates an apoptotic nucleus and the white arrowheads indicate multinucleate cells. (C) Apoptosis induced by
compound 11e was confirmed using annexin V/PI staining and flow cytometry. The fraction of annexin V-positive COLO 205 cells was 5.5% prior
to treatment and 7.6%, 12.7%, 20.9% and 21.8% after treatment with 11e for 12, 24, 36 and 48 h respectively. Scale bar = 20 μm.
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11e-induced apoptosis associated with
caspase-3, caspase-8, caspase-9 and
PARP cleavage
To confirm the possibility that 11e-induced apoptosis is
related to activation of the intrinsic or extrinsic signalling
pathway, COLO 205 cells were treated with 50 nM of 11e for
6, 12, 24, 36 and 48 h, and then the activities of caspase-3,
caspase-8 and caspase-9 were determined using a Western
blot assay. As shown in Figure 10, 11e induced significant
caspase-3, caspase-8 and caspase-9 activity. Results from the
Western blot assay also indicated that 11e induced PARP
cleavage, which is an important apoptosis marker. PARP is
cleaved by caspase-3 between Asp214 and Gly215 to yield p85
and p25 fragments.
Intrinsic apoptotic pathway proteins are
modulated during 11e-induced apoptosis
The mitochondria are key organelles in the control of apop-
tosis. Accordingly, we investigated whether 11e was capable
of inducing depolarization of the mitochondrial membrane
potential (Δψm) using JC-1, a lipophilic fluorescent cation
that incorporates into the mitochondrial membrane. COLO
205 cells were treated with 50 nM of 11e for 6, 12, 24, 36 and
48 h, followed by staining with JC-1, to confirm apoptosis as
the cause of decreased Δψm. As shown in Figure 11A, in
healthy cells with high mitochondrial Δψm, JC-1 spontane-
ously formed complexes known as JC-1 polymer (P2), which
showed intense red fluorescence (0 h). Over time, the per-
centage of cells with reduced red fluorescence (P3) showed a
significant increase. This effect is indicative of a change in
Δψm in the population in which apoptosis was induced
(6–36 h). Moreover, it is well known that the dissipation of
Δψm causes release of cytochrome c, Apaf-1, apoptosis-
inducing factor (AIF) and Endo G into the cytosol, with
consequent activation of the execution phase of apoptosis. In
this study, we also demonstrated that mitochondrial cyto-
chrome c, Apaf-1, AIF and Endo G were released into the
cytosol during 11e-induced apoptosis (Figure 11B).
Bcl-2 family proteins are key regulators of mitochondrial-
related apoptotic pathways (Zhai et al., 2008; Roy et al.,
2014). Some of these proteins, such as Bcl-2 and Bcl-xL, are
anti-apoptotic (prosurvival) proteins, whereas others, such as
Bad, Bax and Bid, are pro-apoptotic proteins. The Bcl-2 and
Bcl-xL proteins are located in the outer mitochondrial
membrane and are necessary for maintaining mitochondrial
integrity. Furthermore, phosphorylation is a common char-
acteristic of destabilized mitochondria. The balance of pro-
and anti-apoptotic Bcl-2 proteins influences the sensitivity of
cells to apoptotic stimuli (Brunelle and Letai, 2009). Previous
research has shown that an increase in the ratio of Bax/Bcl-2
within a cell predisposes it to certain apoptotic stimuli. Bax
and Bak induce the release of cytochrome c and loss of mito-
chondrial membrane potential, whereas Bcl-2 and Bcl-xL
inhibit these effects. Because 11e results in caspase-9 activa-
tion, which is also a mitochondria-mediated caspase, we
sought to determine whether 11e would affect the protein
levels of these Bcl-2 family members. To confirm the involve-
ment of Bcl-2 protein activity in 11e-induced apoptosis,
COLO 205 cells were treated with 50 nM of 11e for 6, 12, 24,
36 and 48 h. As shown in Figure 11C, results indicated that
11e reduced anti-apoptotic Bcl-2 and Bcl-xL levels and
increased proapoptotic Bax and Bad levels, leading to changes
in the Bax/Bcl-2 ratio and the release of cytochrome c, which
in turn activates cleavage of caspase-9 and activation of
caspase-3. These results demonstrate that 11e-induced cell
apoptosis involves the mitochondria-dependent pathway in
COLO 205 cells.
Figure 6
Effects of 11e on the cytotoxicity of COLO 205 cells. (A) Chemical
structure of 11e. (B) COLO 205 cells were exposed to different
concentrations of 11e for 48 h. (C) COLO 205 cells were exposed to
0, 10, 25, 50, 75 and 100 nM 11e for 24, 48 and 72 h. Cell viability
was assessed using the MTT assay. The data are presented as mean ±
SEM of three independent experiments. Cells without treatment
served as a control. *P < 0.001 versus control.
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Effects of 11e on death receptors and
expression of their ligands
Upon binding to their ligands, death receptors trigger apop-
tosis by stimulating caspase-8 mediated caspase cascades. In
this study, expression of several death receptors (Fas, DR4 and
DR5) and their ligands (FasL and TRAIL) were detected in
COLO 205 cells (Figure 12). Compound 11e treatment
induced an increase in DR5, but did not alter Fas levels. These
results suggest that DR5 up-regulation plays an important
role in 11e-mediated apoptosis through the extrinsic signal-
ling pathways in COLO 205 cells.
11e-induced apoptosis is mediated via JNK
signalling pathway
MAPK respond to extracellular stimuli and regulate cellular
activities, such as gene expression, mitosis, differentiation
and cell survival/apoptosis. COLO 205 cells were treated with
50 nM of 11e for 6, 12, 24, 36 and 48 h to investigate the
effects of 11e on ERK1/2, JNK and p38 signalling pathways.
As shown in Figure 13, 11e decreased phospho-ERK1/2, p38
and phospho-p38 expression and induced JNK phosphoryla-
tion after 12 h incubation. These observations suggest that
JNK activation is involved in 11e-induced apoptosis.
Discussion and conclusion
In our continuing investigations of 4-PQ, new
4-benzyloxyquinolin-2(1H)-one derivatives (7a–e ∼ 15a–e)
were designed and synthesized. In these novel molecules, the
2-quinolone central scaffold of 4-PQ is retained, but the
linkage to the 4-phenyl aromatic ring has been extended by
the addition of a CH2O moiety, making a more flexible
bridge. Nine compounds (7e, 8e, 9b, 9c, 9e, 10c, 10e, 11c
and 11e) displayed high potency against HL-60, Hep3B,
H460 and COLO 205 cells (IC50 < 1 μM) without affecting
normal human Detroit 551 cells (IC50 > 50 μM). Among them,
11e exhibited the highest potencies against these four
tumour cell lines with IC50 values of 0.014, 0.035, 0.04
and 0.028 μM respectively. Notably, compound 11e
Figure 7
11e delays M phase progression and caused microtubule disassembly in cultured cells. (A) Flow cytometry analysis of cell cycle distribution in
COLO 205 colon cancer cell line treated with 50 nM of 11e for 0, 6, 12, 24, 36 and 48 h. (B) The effect of 11e on the microtubule formation
in COLO 205 cells. Cells were incubated with 0.1% DMSO, 50 nM 11e, 1 μM colchicine or 1 μM taxol for 24 h. Immunofluorescence for α-tubulin
(green) and PI nuclear staining (red). Cells were visualized using confocal microscopy.
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exhibited improved cytotoxicity in comparison with 6,7-
methylenedioxy-4-(2,4-dimethoxyphenyl)quinolin-2(1H)-
one, the most potent 4-PQ analog previously reported (IC50
0.4, 1.0, 0.9 and 7.4 μM against the four tumour cell lines)
(Chen et al., 2013b). SAR study on these new compounds
revealed that a 3′,5′-dimethoxybenzyloxy moiety, linked at
the 4-position of a 6-methoxy-2-quinolone backbone is most
favourable for increased antiproliferative activity.
In the NCI-60 assay, compounds 9b, 9c, 9e and 11e
showed broad-spectrum antitumour properties at the
nanomolar level. In particular, compound 11e not only
inhibited the growth of numerous cancer cell lines at the low
micromolar range, but also exhibited high selectivity against
COLO 205 (colon cancer). Furthermore, the preliminary bio-
logical studies indicated that compound 11e inhibited cell
growth and induced apoptosis in COLO 205 cells. Based on
these results, compound 11e has been identified as a prom-
ising hit and candidate for future development.
Investigation of the anticancer activity of this novel
2-quinolone analogue provided data indicating that 11e
exerted highly antiproliferative activity and cytotoxicity
against COLO 205 cells in a dose- and time-dependent
manner (Figure 6C), resulting in G2/M arrest and apoptosis
(Figure 7A). Microtubules are important cellular targets for
anticancer therapy because of their key role in mitosis (Perez,
2009). Microtubule-targeting agents, including the taxanes,
Vinca alkaloids and colchicine, bind to different sites on
tubulin and affect stabilization or destabilization of microtu-
bule dynamics (Dumontet and Jordan, 2010). To clarify the
molecular regulation of 11e in G2/M arrest, we first exam-
ined its influence on microtubules. Our data showed that 11e
results in the depolymerization of microtubules in COLO 205
cells and disrupts intracellular microtubule networks in
intact cells, as shown in the immunofluorescence studies
(Figure 7B). Treatment of 11e for 24 h resulted in microtu-
bule changes similar to those induced by colchicine. The
docked conformation of 11e was selected as a working model
(Figure 8), based on its similarity to the crystal structure of
the bound conformation of DAMA-colchicine in tubulin. The
superimposition of 11e and DAMA-colchicine based on A
ring showed an extensive overlap of the 2-quinolone cores
and C rings of both molecules had similar orientations. This
result supports the hypothesis that the spatial arrangement of
the aromatic A and C ring plays a crucial role in the activity
and binding of compounds that bind to the main binding site
of the colchicine domain on α- and β-tubulin. These findings
characterize 11e as an antimitotic agent.
Previous investigations have reported that cyclin
B1/CDK1 complexes are involved in the regulation of G2/M
phase and M phase transitions (Peters, 2006; Yang et al.,
Figure 8
The docked binding mode of 11e is shown with the binding site of tubulin (PDB entry 1SA0). The figures were performed using PyMol. (A) The
binding mode of DAMA-colchicine (red stick model) and tubulin. (B) The binding mode of 11e (yellow stick model) and tubulin. (C)
DAMA-colchicine and 11e occupy similar binding space in tubulin (shown as surface of tubulin cavity). (D) The superimposition of DAMA-
colchicine and 11e.
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2009). Our data showed increased levels of cyclin B1/CDK1
after 11e treatment within 6 to 24 h of treatment (Figure 9A).
These results reveal that treatment with 11e not only directly
contributes to disrupting microtubules in COLO 205 cells,
but also induces accumulation of cyclin B1/CDK1. Aurora
kinases also play important roles in chromosome alignment,
segregation and cytokinesis during mitosis (Andrews, 2005;
Fu et al., 2007; Yang et al., 2007). Our data showed decreased
aurora A, phospho-aurora A, aurora B, phospho-aurora B and
phospho-H3 expression after 11e treatment (Figure 9B).
Therefore, 11e inhibited the growth of COLO 205 cells and
arrested cells at the G2/M phase through the inactivation of
aurora kinases.
Apoptosis induced by antimitotic agents is known to be
related to alterations of cellular signalling pathways (Bhalla,
2003; Jordan and Wilson, 2004). Compound 11e not only
demonstrated broad-spectrum anticancer effects but also pro-
duced apoptosis, as shown by the findings of annexin V/PI in
COLO 205 cells. Apoptosis regulators have been extensively
studied and provide the basis for novel therapeutic strategies
aimed at promoting tumour cell death (Lowe and Lin, 2000;
Ghobrial et al., 2005). To investigate the involvement of apo-
ptosis pathways in 11e-mediated cytotoxicity, we assessed
the caspase cascades. The results showed that 11e induced
significant caspase-3, caspase-8 and caspase-9 activities
(Figure 10). Moreover, caspase 8 is one of the caspases
involved in the extrinsic pathway, while caspase-9 acts in the
intrinsic pathway.
The intrinsic pathway is initiated with loss of membrane
potential in mitochondria and then the release of cyto-
chrome c, AIF and Endo G from the mitochondria into the
cytosol. Cytochrome c in conjunction with Apaf-1 and
procaspase-9 form an apoptosome. This complex promotes
the activation of caspase-9, which in turn activates caspase-3,
leading to apoptosis (Green and Reed, 1998; Dlamini et al.,
2004; Eberle et al., 2007). Proteolytic degradation of PARP, a
substrate of caspase-3, indicated that caspase activation was
involved in 11e-induced apoptosis in COLO 205 cells
(Figure 10B). To confirm that mitochondria-mediated intrin-
sic pathways were involved in 11e-mediated apoptosis, we
further monitored the changes of mitochondrial membrane
potential. Our data showed a loss of mitochondrial
membrane potential in cells treated with compound 11e
Figure 9
Compound 11e increased G2/M phase checkpoint protein expres-
sion. COLO 205 cells were treated with 50 nM 11e for the indicated
time periods and lysed for protein extraction. Protein samples (40 μg
protein per lane) were separated using 10% SDS-PAGE and subjected
to immunoblotting with antibodies specific to cyclin B1, CDK1,
phospho-CDK1 (A), aurora A, phospho-aurora A, aurora B, phospho-
aurora B, H3, phospho-H3 (B) and β-actin (n = 3 independent experi-
ments). β-Actin was used as a loading control.
Figure 10
Compound 11e induced caspase-3, caspase-8 and caspase-9 activity
in COLO 205 cells. COLO 205 cells were treated with 50 nM 11e for
the indicated times and lysed for protein extraction. Protein samples
(40 μg protein per lane) were separated using 10% SDS-PAGE and
subjected to immunoblotting with antibodies specific to caspase-9,
caspase-8, caspase-3, PARP and β-actin (n = 3 independent experi-
ments). β-Actin was used as a loading control.
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Figure 11
Compound 11e induced the mitochondrial apoptosis pathway in COLO 205 cells. (A) Effects of 11e on mitochondrial membrane potential in
COLO 205 cells. Cells (1 × 106 cells·mL−1) were untreated or treated with 11e (50 nM, 6–48 h) to induce apoptosis. Cells were stained with JC-1
and analysed by flow cytometry. (B) COLO 205 cells were treated with 50 nM 11e for the indicated times and lysed for protein extraction. Protein
samples (40 μg protein per lane) were separated using 10% SDS-PAGE and subjected to immunoblotting with antibodies specific to AIF, Endo G,
Apaf-1, cytochrome c and β-actin (n = 3 independent experiments). (C) Compound 11e affected Bcl-2 family proteins in COLO 205 cells. COLO
205 cells were treated with 50 nM 11e for the indicated times and lysed for protein extraction. Protein samples (40 μg protein per lane) were
separated using 10% SDS-PAGE and subjected to immunoblotting with antibodies specific to Bid, Bax, Bad, Bcl-xL, Bcl-2 and β-actin (n = 3
independent experiments). β-Actin was used as a loading control.
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(Figure 11A). Figure 11B shows that compound 11e induce a
time-dependent effect on cytochrome c, AIF and Endo G
translocation from the mitochondria into the cytosol. The
Bcl-2 family proteins largely mediate the mitochondrial
apoptotic pathway. These proteins include proapoptotic
members, such as Bax and Bad, which promote mitochon-
drial permeability, and anti-apoptotic members, such as Bcl-2
and Bcl-xL, which inhibit the proapoptotic protein effects
or inhibit the mitochondrial release of cytochrome c
(Antonsson et al., 1997; Bagci et al., 2006). Overexpression of
Bcl-2 increases cell survival by suppressing apoptosis. Bax
levels increase in conjunction with Bax inhibition of Bcl-2
and the cells undergo apoptosis (Gross et al., 1999; Vela et al.,
2013). The present results showed that 11e treatment
resulted in a decrease in the level of anti-apoptotic proteins
Bcl-xL and Bcl-2 as well as an increase in the level of proapo-
ptotic protein Bax and Bad (Figure 11C).
The extrinsic pathway is initiated by ligation of trans-
membrane death receptors (Fas, DR4/5 and TNFR1) with their
respective ligands (FasL, TRAIL and TNFα) triggering the for-
mation of a death-inducing complex to active caspase-8,
which in turn cleaves and activates caspase-3 (Ashkenazi and
Dixit, 1998; Thorburn, 2004). Enhanced TRAIL expression
and stimulation of DR4- and/or DR5-induced apoptosis has
been shown in certain types of cancers, including colon,
ovarian, prostate, bladder and chronic lymphocytic leukae-
mia (O’Flaherty et al., 2006; Lee et al., 2011; Thomas et al.,
2013). In the present study, we found that 11e treatment
up-regulated the expression of the DR5 protein and influ-
enced the expression of TRAIL (Figure 12). Caspase-8 is acti-
vated by the death receptor. Activated caspase-8 can cleave
and activate downstream caspase-3. On the other hand,
caspase-8 can induce Bid cleavage and the cleaved Bid causes
cytochrome c efflux from mitochondria, then activation of
caspase-9 and caspase-3. We showed that 11e induced the
cleavage of full-length Bid producing truncated Bid (t-Bid,
17 kDa), which translocated to the mitochondria. These find-
ings together suggest that 11e induced apoptosis by activat-
ing both intrinsic and extrinsic signalling pathways.
MAPKs, which belong to a large family of serine-
threonine kinase, are critical mediators of the cell membrane
to nucleus signal transduction in response to various extra-
cellular stimuli (Pearson et al., 2001; Fang and Richardson,
2005). The three major subfamilies of MAPK include the
ERKs, JNK and p38. Recent studies have shown that JNKs and
p38 pathways are associated with increased apoptosis,
whereas the ERK1/2 pathway is shown to suppress apoptosis.
In our experiments, we observed that after 24 h incubation,
11e increased levels of phosphorylated JNK in COLO 205
cells (Figure 13). TRAIL can also activate JNK through the
Figure 12
Compound 11e-induced death receptor apoptosis pathways in
COLO 205 cells. COLO 205 cells were treated with 50 nM 11e for
the indicated times and lysed for protein extraction. Protein samples
(40 μg protein per lane) were separated using 10% SDS-PAGE and
subjected to immunoblotting with antibodies specific to Fas, TNFR1,
DR4, DR5 (A), FasL, TNF-α, TRAIL (B) and β-actin (n = 3 independent
experiments). β-Actin was used as a loading control.
Figure 13
Expression of MAPKs in the 11e-treated COLO 205 cells. COLO 205
cells were treated with 50 nM 11e for the indicated times and lysed
for protein extraction. Protein samples (40 μg protein per lane) were
separated using 10% SDS-PAGE and subjected to immunoblotting
with antibodies specific to ERK1/2, phospho-ERK1/2, JNK, phospho-
JNK, p38, phospho-p38 and β-actin (n = 3 independent experi-
ments). β-Actin was used as a loading control.
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adaptor molecules TRAF2 and RIP (Lin et al., 2000) and JNK is
activated by TRAIL in colon cancer cells (Mahalingam et al.,
2009). In our study, 11e-activated JNK might play a mediated
role in TRAIL-induced apoptosis in COLO 205 cells.
In summary, our present study has identified novel
4-benzyloxyquinolin-2(1H)-ones as potent inducers of apop-
tosis in a range of cancer cells. This new series of compounds
could be further exploited to obtain analogues with higher
activity for cancer chemotherapy. Figure 14 summarizes the
molecular signalling pathways induced by 11e. We demon-
strated that compound 11e exhibited broad-spectrum anti-
cancer properties against several solid tumour cells and
exerted potential anticancer activity against COLO 205 cells.
Based on our mechanistic results, compound 11e caused
tubulin depolymerization, aurora A and aurora B inactiva-
tion, G2/M phase arrest, polyploidy and subsequent apopto-
sis via both intrinsic and extrinsic apoptotic pathways. These
findings suggest that compound 11e has potential use as a
novel therapeutic agent for the treatment of human colon
carcinoma.
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Figure S8 Finger print of in vitro GI50, TGI and LC50 of com-
pound 9c.
Figure S9 One Dose Mean Graph Program (10 μM) of com-
pound 9e.
Figure S10 Five doses response curves of compound 9e.
Figure S11 In vitro GI50, TGI and LC50 of compound 9e.
Figure S12 Finger print of in vitro GI50, TGI and LC50 of
compound 9e.
Figure S13 One Dose Mean Graph Program (10 μM) of com-
pound 11e.
Figure S14 Five doses response curves of compound 11e.
Figure S15 In vitro GI50, TGI and LC50 of compound 11e.
Figure S16 Finger print of in vitro GI50, TGI and LC50 of
compound 11e.
Appendix S1 Spectral copies of 1HNMR and 13C NMR of the
synthetic compounds (5a–i and 7a–e ∼ 15a–e).
Appendix S2 Spectral copies of Mass and IR of the synthetic
compounds (5a–i and 7a–e ∼ 15a–e).
Appendix S3 The two-dimensional NMR spectra of com-
pound 11e and NCI-60 results of compounds (9b, 9c, 9e and
11e).
Appendix S4 Physical and spectroscopic assignments of the
synthetic compounds (5a–i and 7a–e ∼ 15a–e).
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